FY2025 Earnings Forecast for ABVX Issued By Lifesci Capital

ABIVAX Société Anonyme (NASDAQ:ABVX) – Analysts at Lifesci Capital issued their FY2025 earnings per share (EPS) estimates for shares of ABIVAX Société Anonyme in a research report issued to clients and investors on Tuesday, March 25th. Lifesci Capital analyst S. Slutsky anticipates that the company will post earnings of ($3.14) per share for the year. The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share.

ABVX has been the topic of a number of other reports. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price target on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th. Finally, JMP Securities restated a “market outperform” rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $38.00.

ABIVAX Société Anonyme Stock Performance

ABIVAX Société Anonyme stock opened at $7.09 on Wednesday. The stock’s 50 day moving average is $6.78 and its 200 day moving average is $8.42. ABIVAX Société Anonyme has a twelve month low of $5.50 and a twelve month high of $16.63.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ABVX. ADAR1 Capital Management LLC increased its holdings in ABIVAX Société Anonyme by 190.1% in the 4th quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company’s stock worth $11,078,000 after buying an additional 991,781 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of ABIVAX Société Anonyme by 10.7% during the 4th quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company’s stock valued at $10,732,000 after acquiring an additional 141,710 shares during the last quarter. Nantahala Capital Management LLC grew its stake in shares of ABIVAX Société Anonyme by 45.7% in the fourth quarter. Nantahala Capital Management LLC now owns 1,436,047 shares of the company’s stock worth $10,512,000 after acquiring an additional 450,413 shares during the period. Millennium Management LLC raised its holdings in shares of ABIVAX Société Anonyme by 44.2% during the fourth quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock valued at $6,816,000 after purchasing an additional 285,542 shares during the last quarter. Finally, Citadel Advisors LLC lifted its position in ABIVAX Société Anonyme by 83.5% during the fourth quarter. Citadel Advisors LLC now owns 855,676 shares of the company’s stock valued at $6,264,000 after purchasing an additional 389,247 shares during the period. 47.91% of the stock is owned by institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.